Background: Carbapenems are frequently used as a last resort to treat infections caused by multidrug-resistant Gram-negative organisms, thus carbapenem-non-susceptible Enterobacteriaceae (CNSE) is an emerging health threat.
Introduction
Carbapenem-non-susceptible Enterobacteriaceae (CNSE) constitute an emerging health threat. This loss of susceptibility to carbapenems results from different mechanisms: carbapenemase production [carbapenemase-producing Enterobacteriaceae (CPE)] or a combination of enzymatic mechanisms, such as ESBL or overproduction of AmpC b-lactamase with efflux and reduced outermembrane permeability.
1,2 Plasmid-encoded carbapenemases are a particular threat as they are transmissible between different bacterial species. CPE have been reported worldwide in recent years, notably due to the rapid spread of carbapenem-hydrolysing oxacillinase OXA-48 and New Delhi metallo-b-lactamase (NDM) produced by Enterobacteriaceae. 3, 4 The overall prevalence of carbapenem resistance in 2014 in Europe for Klebsiella pneumoniae was 7.3% and varied considerably between countries (from 0% in some northern countries to nearly 62.3% in Greece). 5 In France, outbreaks of CPE have been continually reported since 2009, with the greatest increase in the last quarter of 2014, mainly due to the spread of OXA-48-producing Enterobacteriaceae. 3 The proportion of K. pneumoniae with decreased susceptibility to carbapenems was 0.9% in 2014 in France. 6 Carriage or infection by CPE is both a major clinical and public health concern, which explains why controlling the spread of MDR bacteria is a priority.
The aim of the present study was to characterize CNSE isolates in North-Eastern France, to determine risk factors for CNSE carriage and to describe outcomes for patients harbouring these strains. We performed a multicentre matched case-control study, by comparing clinical data from two populations: cases harbouring a CNSE and controls harbouring carbapenem-susceptible Enterobacteriaceae (CSE).
Materials and methods

Study design and population
The study was conducted in four teaching hospitals (Besançon, Dijon, Reims and Strasbourg) and two general hospitals (Colmar and Troyes) in North-Eastern France. Together the seven hospitals provided 8380 beds and almost 459 000 admissions during the year-long period of this investigation.
Patients aged 18 years who were colonized or infected by an enterobacterial isolate between 1 January and 31 December 2012 were eligible for inclusion in the study. Cases were randomly selected among the 216 CNSE isolated in the centres. For each case, the matched controls comprised two subsequent patients colonized or infected with the same species, but which was carbapenem susceptible.
Data collection was performed by clinical research assistants retrospectively. Potentially relevant sociodemographic and clinical data were extracted from the patient medical records or directly from physicians if needed. Patients were informed according to French biomedical research law. Data collected included age, date of hospital admission, type and site of infection, MDR carriage, presence of concomitant infection(s), comorbidities, use of antibiotics as well as prior surgery, invasive procedures, history of prior antibiotic use (within the last 6 months) and prior hospitalization (within the last 5 years). Comorbidity was classified according to the Charlson comorbidity index. 7 An age-adjusted comorbidity index was calculated by weighting individual comorbidities and adding 1 point per decade to ages .40 years. 8 Patient status at 1 month was also noted, as assessed by the progression of infection, the need for surgery or ICU admission, discharge from the hospital and mortality.
Microbiological analysis
Bacterial isolates were selected from clinical or screening samples: for screening, samples were plated on chromIDR V R ESBL agar plates (bioMérieux). Cases were defined as patients from whom isolates were obtained that were intermediate or resistant to at least one carbapenem. All non-duplicate Enterobacteriaceae isolates non-susceptible to ertapenem (MIC .0.5 mg/L, determined using Etest V R strips; bioMérieux) were collected in the different centres and sent to the Reims Hospital laboratory. The first isolate of each patient was selected for inclusion in the study.
Identification was performed using MALDI-TOF (Bruker Daltonics, Bremen, Germany) and antibiotic susceptibility determined by the disc diffusion method according to EUCAST guidelines. 9 As previously described, ESBL and AmpC overexpression were detected by the double-disc synergy test and disc diffusion method performed on Mueller-Hinton agar supplemented with cloxacillin (250 mg/L), respectively. 10 Carbapenemase-encoding genes bla KPC , bla VIM , bla IMP , bla NDM , bla OXA-23 -like, bla OXA-24 -like, bla OXA-58 -like and bla OXA-48 -like were screened using multiplex PCRs and completed with simplex PCRs for bla IMI and bla GES as described elsewhere. 11 All the bla OXA-48 -like genes detected were subsequently sequenced. Genes bla TEM , bla SHV , bla CTX-M and bla OXA were detected by PCR using specific primers and sequenced as previously described for all the ESBL-producing isolates. 12 For the analysis of efflux and reduced outer-membrane permeability, quantitative real-time reverse transcriptase PCR was performed to determine the expression of ompF, ompC porin genes and the acrB efflux pump gene, relative to the rpoB housekeeping gene, as described elsewhere. 1 
Statistical analysis
Quantitative variables are presented as mean + standard deviation (SD), and qualitative variables as number (percentage). Univariate analysis was performed to select candidate variables for inclusion in the multivariable analysis. Variables with P , 0.20 were included in the multivariate model. Univariate and multivariate analyses using conditional logistic regression were conducted to identify independent risk factors for CNSE carriage. All tests were two-sided and P , 0.05 was considered statistically significant. All analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Participant characteristics
One hundred and sixty-five patients were included, 55 cases (patients with CNSE) and 110 controls (patients with CSE) ( Table 1) . Forty-six per cent of patients were men (n " 75). The majority of samples were diagnostic samples from infections (58.0%, n " 94) (the others were samples from colonization sites). Anatomical sites of infection were mainly urine (35.1%, n " 33), blood (17.0%, n " 16) or respiratory secretions (14.9%, n " 14). Patients were hospitalized in medical (46.7%, n " 71), surgical (24.3%, n " 37), intensive care (15.8%, n " 24) or rehabilitation units (11.2%, n " 17). We found that 22.2% of patients (n " 35) had concomitant infection(s) combined with the CNSE isolation (infection or colonization): respiratory infections (n " 10), urinary infections (n " 9), gastrointestinal infections (n " 6), cutaneous infections (n " 7) and sepsis (n " 2) (unknown origin, n"1). Most of patients had comorbidities (74.1%, n " 120), including peripheral vascular disease (23.3%, n " 28), chronic respiratory disease (18.3%, n " 22), non-complicated diabetes (29.2%, n " 35), kidney disease (33.3%, n " 40) and haematological/solid malignancies (24.2%, n " 29). Furthermore, almost half of the patients had had surgery in the year prior to inclusion (46.3%, n " 74), such as orthopaedic surgery (23.0%, n " 17), intestinal surgery (21.6%, n " 16) or vascular surgery (12.2%, n " 9). Most of the patients had had recent invasive procedures (84.5%, n " 136), for instance peripheral or central venous access catheters, urinary catheters or intubation/ mechanical ventilation. One hundred and twenty-four (78.5%) patients had stayed in a French hospital within the past 5 years.
CNSE characterization
The 55 CNSE isolates were mostly E. cloacae (65.5%, n " 36) and K. pneumoniae (25.5%, n " 14) ( Table 2 ). Forty per cent of CNSE (n " 22) produced a carbapenemase: all were OXA-48-producing strains and 21 of 22 came from the same centre. Overall, these CPE isolates were E. cloacae (n " 14) and K. pneumoniae (n " 8).
The non-CPE strains (60%, n " 33) had various associations of ESBL and/or overproduced AmpC b-lactamase in combination with efflux and reduced outer-membrane permeability. All Enterobacter spp. overproduced chromosomal AmpC b-lactamase, and 31.8% also produced an ESBL. Conversely, all K. pneumoniae isolates Carbapenem-non-susceptible Enterobacteriaceae: factors and outcomes JAC were ESBL producers. Moreover, at least 88.5% (n " 23) of these non-CPE strains presented efflux and reduced outer-membrane permeability.
Risk factors and outcomes of CNSE carriage
The main risk factors for CNSE carriage for patients harbouring CNSE, determined by univariate analysis, are shown in Table 3 . The presence of concomitant infection(s) (P , 0.0001), a high age (P " 0.01), antibiotic use within the last 6 months (P " 0.014), particularly carbapenems (P " 0.03) and fluoroquinolones (P " 0.016), hospital stay within the last 5 years (P " 0.043) and nosocomial acquisition (P " 0.0006) were significantly associated with CNSE carriage. Moreover, in infected patients, 90.0% of patients with CNSE had received antibiotics within the last 6 months compared to 67.2% of patients infected with CSE (P , 0.0001). For patients currently on antibiotics at the time of sampling, 47.2% of patients with CNSE had been receiving antibiotics compared to 37.1% of patients with CSE, but this difference was not significant (P " 0.250).
The five variables of associated factors with P , 0.20 included in the multivariate analysis were age, presence of concomitant infection(s), antibiotics used within the last 6 months, hospital stay within the last 5 years and nosocomial infection. The multivariable analysis showed several independent risk factors for CNSE carriage. The most significant was the presence of concomitant infection(s) (OR: 9.83; 95% CI 2.16-44.64, P " 0.0031). Nosocomial infection (OR: 7.84; 95% CI 1.79-34.36, P " 0.0063) and a high age (OR: 1.07; 95% CI 1.00-1.13, P " 0.038) were also identified as independent risk factors (Table 3) .
In the univariate analysis, infected patients with CNSE had fewer resolved infections at 1 month after inclusion (P " 0.02) than patients infected with CSE, a higher mortality rate (P " 0.0004), as well as a longer hospital stay (fewer discharged at 1 month) (P " 0.02) ( Table 4) . A multivariate analysis of patient mortality and a range of factors, including CNSE carriage, concomitant infection(s), sex, age, hospital stay within the last 5 years, recent invasive procedure, nosocomial infection and Charlson age score index found that CNSE carriage (OR: 6.04; P " 0.0056), Charlson age score index (OR: 1.50; P " 0.028) and nosocomial infection (OR: 29.7; P " 0.0007) were independently associated with increased mortality. Moreover, 44.4% of patients infected with CNSE had an antimicrobial therapy modification at 72 h.
Discussion
In our study, only 40% of CNSE isolates produced a carbapenemase, with the majority of the CNSE being resistant to Muggeo et al.
carbapenems due to a combination of ESBL and/or overproduced AmpC b-lactamase with efflux and reduced outer-membrane permeability. Hence, non-CPE strains, which have been much less monitored and studied than CPE strains, seem to be able to spread between patients in hospital. This is even more surprising for noncarbapenemase-producing E. cloacae, which commonly exhibit chromosomal overproduction of AmpC b-lactamase combined with efflux and reduced outer-membrane permeability, therefore having a non-plasmidic transmission. 1, 13 It was of further interest to note that all of the CPE in our study were OXA-48-producing strains and were mostly isolated in one centre. An increase of autochthonous cases of OXA-48 CPE has been reported in France since 2014, with OXA-48-producing K. pneumoniae and E. coli becoming the most frequent CPE, followed by NDM-, VIM-and KPC-producing Enterobacteriaceae.
3 CPE isolates were ESBL producers, as already described with OXA-48-producing Enterobacteriaceae, 14, 15 probably because of selection for carbapenemase acquisition as a result of selective pressure by carbapenem on ESBL-producing isolates. 16, 17 The results of our matched case-control study revealed several risk factors for CNSE carriage. Interestingly, our multivariate analysis showed that the strongest risk factor was a concomitant infection. More than 44% of patients with CNSE had concomitant infection(s) whereas only 10% of patients with CSE had one, representing an increased risk of 9.8. These concomitant infections were highly diverse, encompassing various bacteria and treatments. To our knowledge, this factor is little studied and this is the first time it has been described as a risk factor. Palacios et al. noted frequent infections in patients from whom CPE were isolated; none the less, they did not extend their study to patients with CNSE. 18 We assume that these patients had enhanced exposure to antibiotics and were more likely to have been hospitalized due to their concomitant infection(s). CNSE isolation was also associated with older age in this survey, as already described for OXA-48 CPE by Dautzenberg et al. 19 Although the OR was low for age, these concomitant infections and high age may reflect a higher level of patient debility, including a microbiota probably modified and more susceptible to the establishment of CNSE.
Not surprisingly, CNSE isolation was also independently associated with nosocomial acquisition, because hospitals remain the most important reservoir of CNSE. The number of CNSE cases acquired in hospitals was notable in our study. This exposure to healthcare has been highlighted by other investigators. 18, 20, 21 However, in contrast to previous studies, we did not find intensive care, comorbidities or invasive procedures to be among the risk factors. [21] [22] [23] [24] Another risk factor for CNSE carriage in our study was exposure to antibiotics, recognized as one of the most prominent risk factors in the literature. [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] By their selective pressure, antibiotics contribute to maintaining CNSE strains in the hospital setting. More patients with CNSE had received antibiotics in the last 6 months than patients with CSE (P " 0.014), a difference even Carbapenem-non-susceptible Enterobacteriaceae: factors and outcomes JAC more significant for infected patients (P , 0.0001). More precisely, the strongest associations were found with carbapenems and fluoroquinolones, which seem to be the two antimicrobial classes most frequently associated with CNSE. 19, 21, [25] [26] [27] [28] [29] 31 In contrast to some previous studies, we did not find cephalosporins and penicillins as risk factors. 20, 27, 28, 32 However, determination of which specific antimicrobial classes were involved is complicated, as the reported results differ significantly according to the methodology and bacteria included. Moreover, some classes previously identified were not evaluable here because of the low number of patients receiving some of them (e.g. glycopeptides, macrolides). 20, 26 Similarly, more patients with CNSE had been receiving antibiotics at the time of sampling than patients with CSE (47.2% versus 37.1%) but this difference was not statistically significant. Of note, exposure to antibiotics in the last 6 months was not identified by the multivariate analysis as an independent risk factor. Rather, it was linked to other risk factors including concomitant and nosocomial infections.
Most studies on outcomes of infections with CNSE indicated a bad prognosis for the patient, as in our study. Indeed, patients infected with CNSE had had fewer resolved infections at 1 month after inclusion, had a higher mortality and a longer hospital stay. This higher rate of death has been commonly reported. 15, 17, 25, 28, 29, 33 The fact that concomitant infection(s) was associated with CNSE raised the question of its implication in the high mortality observed in this study. For this reason, we performed a multivariate analysis focusing on mortality with all its potential factors, allowing us to rule out the involvement of concomitant infection(s), as it was not associated with mortality in this analysis. The poorer outcomes seen here could be explained by the delay in initiating appropriate antibiotic therapy, as previously described. 18, 21 Indeed, in cases of CNSE, empirical treatment was often microbiologically inadequate, because these bacteria require the use of broad-spectrum antibiotics. 33 Empirical treatment of Enterobacteriaceae commonly consists of third-generation cephalosporins and CNSE are resistant to these antibiotics in most cases, as well as to carbapenems, and as MDR pathogens, they are also often resistant to other classes of antibiotics, leaving few effective treatment options and making their eradication difficult. 33 In our study, 44.4% of patients infected with CNSE had antibiotic therapy modified at 72 h, reflecting a delay in the administration of adequate therapy. Furthermore, there was often a lack of re-evaluation of antimicrobial therapies at 72 h by doctors, which worsens the situation. Many studies reported a delay of several days between the onset of infection with CPE and effective treatment, which explains the higher mortality observed with these bacteria. 15, 33 Our study had some limitations. First, the sample size of patients included was relatively small, as often found in studies assessing risk factors of rare MDR bacteria. Moreover, as the selection of bacteria from colonization sites was made on the chromIDR V R ESBL plate, OXA-48 producer strains susceptible to thirdgeneration cephalosporins were not detected.
In conclusion, the risk factors for CNSE carriage and/or infection identified in our study and the worse outcome of these patients reiterate the concerns about the spread of carbapenem resistance in Enterobacteriaceae and highlight the importance of early detection of all types of CNSE (CPE but also non-CPE). A re-evaluation of antimicrobial therapy after bacteriological investigation is crucial for patients infected with CNSE. Finally, this study highlights the critical importance of limiting the use of carbapenems and fluoroquinolones.
